Arrowhead Pharmaceuticals, Inc. (ARWR) Earnings History
Net Loss29 years of earnings data (1997–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Arrowhead Pharmaceuticals, Inc. (ARWR) Earnings Overview
As of June 22, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) reported trailing twelve-month net income of -$301M, reflecting +99.8% year-over-year growth. The company earned $-2.11 per diluted share over the past four quarters, with a net profit margin of -0.2%.
Looking at the long-term picture, ARWR's historical earnings data spans multiple years. The company achieved its highest annual net income of $68M in fiscal 2019.
Arrowhead Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ALNY ($577M net income, 8.4% margin), NTLA (-$395M net income, -609.9% margin), BEAM (-$65M net income, -57.2% margin), ARWR has room to improve margins relative to the peer group. Compare ARWR vs ALNY →
ARWR Earnings vs Peers
Earnings metrics vs comparable public companies
ARWR Historical Earnings Data (1997–2025)
29 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$2M | +99.7% | $98M | $-0.01 | -0.2% | 11.9% |
| 2024 | -$599M | -192.0% | -$601M | $-5.00 | -16882.4% | -16927.1% |
| 2023 | -$205M | -16.6% | -$205M | $-1.92 | -85.3% | -85.2% |
| 2022 | -$176M | -25.0% | -$179M | $-1.67 | -72.4% | -73.4% |
| 2021 | -$141M | -66.6% | -$149M | $-1.36 | -101.9% | -107.8% |
| 2020 | -$85M | -224.4% | -$93M | $-0.84 | -96.1% | -105.9% |
| 2019 | $68M | +224.8% | $61M | $0.69 | 40.3% | 36.3% |
| 2018 | -$54M | -58.4% | -$56M | $-0.65 | -337.3% | -346.5% |
| 2017 | -$34M | +57.9% | -$37M | $-0.47 | -109.5% | -117.8% |
| 2016 | -$82M | +11.1% | -$82M | $-1.34 | -51614.6% | -51627.1% |
| 2015 | -$92M | -56.8% | -$96M | $-1.60 | -24068.3% | -25124.1% |
| 2014 | -$59M | -88.3% | -$53M | $-1.25 | -33503.0% | -30443.6% |
| 2013 | -$31M | -47.4% | -$25M | $-1.30 | -10729.2% | -8471.3% |
| 2012 | -$21M | -575.2% | -$21M | $-1.90 | -14383.6% | -14358.6% |
| 2011 | -$3M | +45.8% | -$10M | $-0.44 | -1056.6% | -3319.5% |
| 2010 | -$6M | +70.1% | -$9M | $-0.90 | -931.2% | -1419.5% |
| 2009 | -$19M | +28.7% | -$20M | $-4.27 | -513.8% | -520.5% |
| 2008 | -$27M | +9.5% | -$35M | $-6.91 | -2078.7% | -2685.9% |
| 2007 | -$30M | -57.6% | -$38M | $-8.35 | -2477.7% | -3141.4% |
| 2006 | -$19M | -177.1% | -$20M | $-5.95 | -3190.4% | -3439.9% |
| 2005 | -$7M | -171.1% | -$10M | $-2.61 | -1160.5% | -1624.0% |
| 2004 | -$3M | -2554.6% | -$3M | $-1.88 | -1287.9% | -1370.7% |
| 2003 | $-95,238 | +61.3% | $-94,438 | $-11.78 | - | - |
| 2002 | $-246,207 | -32.5% | -$1M | $-32.47 | -10865.3% | -62498.4% |
| 2001 | $-185,821 | -35.1% | $-106,265 | $-25.97 | -1995.5% | -1141.2% |
| 2000 | $-137,553 | -123.2% | $-109,235 | $-19.48 | -552.9% | -439.1% |
| 1999 | $593,003 | +459.3% | $-56,216 | $59.30 | 1602.8% | -151.9% |
| 1998 | $-165,025 | +80.7% | $-24,299 | $-5.16 | -273.3% | -40.2% |
| 1997 | $-854,535 | - | $-158,619 | $-85.45 | -1115.7% | -207.1% |
Download Data
Export ARWR earnings history in CSV or JSON format
Free sign-in required to download data
Full Stock Analysis
Deep dive into ARWR consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
29+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ARWR — Frequently Asked Questions
Quick answers to the most common questions about buying ARWR stock.
What is ARWR earnings per share (EPS)?
ARWR trailing twelve-month (TTM) diluted EPS is $-2.11, reflecting +99.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1997 to 2025 is available in the table on this page.
What is Arrowhead Pharmaceuticals, Inc.'s net income?
Arrowhead Pharmaceuticals, Inc. (ARWR) trailing twelve-month net income is $-301M as of 2025. Earnings grew +99.8% year-over-year.
Is ARWR profitable?
ARWR is not currently profitable on a TTM basis, reporting a net loss of $-301M. Net margin is -0.2%. Investors should monitor for a return to profitability.
What is ARWR's earnings growth rate?
ARWR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1997 to 2025.
What are ARWR's profit margins?
Arrowhead Pharmaceuticals, Inc. net profit margin is -0.2%, operating margin is +11.9%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -0.5%.
Is ARWR growing earnings?
Yes, ARWR earnings are accelerating — EPS growth of +99.8% exceeds the 5-year CAGR of N/A. TTM net income reached $-301M. Earnings momentum is strengthening.
What was ARWR's best earnings year?
Arrowhead Pharmaceuticals, Inc.'s highest annual net income on record is $68M, achieved in fiscal year 2019. Earnings history on this page spans 1997 to 2025 and includes all annual and quarterly figures.
What were ARWR's earnings last quarter?
ARWR's most recent reported quarter was Q2 2026. Net income was $-133M with diluted EPS of $-0.93. For a full breakdown of all quarters, see the quarterly earnings table on this page.